Share
Adrian Lam
CorVista Health has appointed Adrian Lam as President and Chief Executive Officer, succeeding Don Crawford, who is retiring after a decade of impactful leadership.
To ensure a seamless transition, Crawford will remain with the company in an advisory role as Special Advisor to the CEO.
During his tenure, Crawford guided CorVista through a period of transformative growth, including the successful launch of two FDA-cleared products - one of which marked a groundbreaking advancement in Pulmonary Hypertension (PH) diagnostics, the first in over 40 years and designated as a Breakthrough Device by the FDA.
Adrian Lam brings over 20 years of global experience across MedTech, BioTech, and Life Science Tools. At Stryker, he led the Advanced Biomaterials R&D Group, contributing to the development of several FDA-approved innovations. He was also a founding executive at Genesis Medtech, where he played a pivotal role in scaling the company from startup to unicorn status in just over a year.
In addition, Lam has experience managing healthcare equity portfolios at Sectoral Asset Management and is the founder of Bioworld Ventures, a healthcare-focused investment and company-building platform. He holds degrees in Biomedical Engineering and Economics from Duke University.
In tandem with the leadership change, Tim Attebery - current Board Director, CEO of Cardiovascular Associates of America, and former CEO of the American College of Cardiology (ACC)—will assume the role of Chairman of the Board.
Related posts
